Who are Omacor®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AMR101, Epanova, Antara (fenofibrate) + Lovaza, Omega 3-Atorvastatin, Omacor + simvastatin, Omega-3-acid ethyl esters 90.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omacor.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Omacor® — Competitive Intelligence Brief

Omacor® (Omacor®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid. Area: Cardiovascular.

marketed Omega-3 fatty acid Hepatic triglyceride synthesis pathway Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Omacor® (Omacor®) — Hospital Universitari Vall d'Hebron Research Institute. Omacor is a prescription omega-3 fatty acid formulation that reduces triglyceride levels by decreasing hepatic triglyceride synthesis and increasing fatty acid oxidation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Omacor® TARGET	Omacor®	Hospital Universitari Vall d'Hebron Research Institute	marketed	Omega-3 fatty acid	Hepatic triglyceride synthesis pathway
AMR101	AMR101	Massachusetts General Hospital	phase 3	Omega-3 fatty acid	Hepatic triglyceride synthesis pathway
Epanova	OMEGA-3-CARBOXYLIC ACIDS	AstraZeneca	marketed	Omega-3 Fatty Acid		2014-01-01
Antara (fenofibrate) + Lovaza	Antara (fenofibrate) + Lovaza	GlaxoSmithKline	marketed	Fibrate + Omega-3 fatty acid combination	PPARα (fenofibrate); GPR120, GPR40 (omega-3 fatty acids)
Omega 3-Atorvastatin	Omega 3-Atorvastatin	Seoul National University Bundang Hospital	marketed	Statin + omega-3 fatty acid combination	HMG-CoA reductase (atorvastatin); GPR120, GPR40 (omega-3 signaling)
Omacor + simvastatin	Omacor + simvastatin	Provident Clinical Research	marketed	Omega-3 fatty acid + HMG-CoA reductase inhibitor (statin)	VLDL production pathway (Omacor); HMG-CoA reductase (simvastatin)
Omega-3-acid ethyl esters 90	Omega-3-acid ethyl esters 90	Pronova BioPharma	marketed	Fibrate-like lipid-lowering agent / Omega-3 fatty acid

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid class)

Estudios Clínicos Latino América · 1 drug in this class
Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
S.L.A. Pharma AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omacor® — Competitive Intelligence Brief. https://druglandscape.com/ci/omacor. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab